Concepedia

David J. Schwalb

DJ

Statistics

Publications

9

Citations

1.2K

H-Index

9

Active since

2004

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Harvard University

David J. Schwalb is an author at Novartis (Switzerland) specializing in pharmacology, drug discovery, and medicinal chemistry.

Publications per year

2004–2014

9

Publications

9

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo

William E. Dowdle, Beat Nyfeler, Jane Nagel et al. · Nature Cell Biology · 2014 · 740 citations

, , +16

Natural products reveal cancer cell dependence on oxysterol-binding proteins

Anthony W. G. Burgett, Thomas B. Poulsen, Kittikhun Wangkanont et al. · Nature Chemical Biology · 2011 · 261 citations · Full text

, , +12

Differential nitros(yl)ation of blood and tissue constituents during glyceryl trinitrate biotransformation <i>in vivo</i>

David R. Janero, Nathan S. Bryan, Fumito Saijo et al. · Proceedings of the National Academy of Sciences · 2004 · 90 citations

, , +13

3-(2-Methoxytetrahydrofuran-2-yl)pyrazoles: a novel class of potent, selective cyclooxygenase-2 (COX-2) inhibitors

Ramani R. Ranatunge, Richard A. Earl, David S. Garvey et al. · Bioorganic & Medicinal Chemistry Letters · 2004 · 50 citations · Full text

, , +11

Selective nitros(yl)ation induced in vivo by a nitric oxide-donating cyclooxygenase-2 inhibitor: a NObonomic analysis

Vijay Dhawan, David J. Schwalb, Matthew J. Shumway et al. · Free Radical Biology and Medicine · 2005 · 22 citations

, , +4

1–5 of 9